LOXL2 stimulates the proliferation of breast cancer cells and contributes to their oncogenic transformation and pathogenesis, suggesting that the development of LOXL2 inhibitors is an effective therapeutic strategy [106]. The gene discussed is LOXL2; the disease is breast cancer.